7,577.00

+2.50

+0.03%

51,978.00

-155.00

-0.30%

28,246.25

+118.75

+0.42%

Russell 2000 Futures

2,817.90

+0.10

+0.00%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,955.40

-14.20

-0.36%

76,793.53

-1,540.69

-1.97%

Crude Oil Dec 26

96.72

+0.26

+0.27%

US Private Equity

10,836.30

-14.33

-0.13%

KSE - Delayed Quote KRW

JW Pharmaceutical Corporation (001067.KS)

49,100.00 -500.00 (-1.01%)

At close: November 2 at 3:30:22 PM GMT+9

Loading Chart for 001067.KS

Chart Range Bar

Interval:

In partnership with ChartIQ

JW Pharmaceutical Proves Efficacy of Key 6mg Dose of Gout Treatment ‘Epaminurad’ in Multinational Phase 3 Trial

JW Pharmaceutical Proves Efficacy of Key 6mg Dose of Gout Treatment ‘Epaminurad’ in Multinational Phase 3 Trial

JW Pharmaceutical Presents Preclinical Results and Global Development Strategy for DDC-02, a Novel Therapeutic Candidate for Rare Neurodevelopmental Disorders

JW Pharmaceutical Presents Preclinical Results and Global Development Strategy for DDC-02, a Novel Therapeutic Candidate for Rare Neurodevelopmental Disorders

Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation

Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

Mobilize your Website

View Site in Mobile | Classic

Share by: